抗結核剤の1回および分服法の比較

概要

論文の詳細を見る
From 1968, we are giving to our patients all the chemotherapeutic drugs once a day. Till then, oral administrations were usually given by 3 divided dosage method. Clinical results and side-effects were compared between 394 cases of the divided daily dosage group and 443 cases of the single group. The background factors of these two groups were fast similar (Table 1). The negative conversion rate for 3 consecutive months of the cases treated with the chemotherapeutic regimen for more than six months was 83.2% in the divided group and 89.9% in the single group. The latter was slightly higher but the difference was statistically not significant. There were also no significant differences between the two groups in the following factors: Primary and secondary drugs (Table 2), extent of the lesion (Table 3), number of combined sensitive drugs (Table 4, Fig. 1), size of cavity (Table 5, 6), bacillary relapse (Table 7) and speed of negative conversion (Fig. 2, 3). The reasons for stopping or changing the regimen before the sixth month showed no connection with the single dosage of drugs (Table 8). The incidence of side-effects was 42 cases or 10.7% in the divided group and 41 cases or 9.3% in the single group. Although gastrointestinal disorders by ethionamide seems to be little more frequent in the single dosage group, the difference was statistically not significant (Table 9) According to the section survey on the drug intake status, 81.8% of cases tolerated 10g of PAS once a day and 78.4% of cases tolerated 0.5 g of ethionamide once a day. In conclusion, we can say that there are no differences in clinical effects and side-effects between single and divided daily dosage methods. The single dosage method may be slightly superior, however in a sense that it is easier to supevise drug administration and the chance of failure in taking the drugs is less.
日本結核病学会の論文

抗結核剤の1回および分服法の比較

スポンサーリンク

概要

著者

関連論文

スポンサーリンク